Boston Scientific continues acquisition trail
This article was originally published in Clinica
Boston Scientific is to acquire Meadox Medicals in a stock deal valued at $425 million. Subject to regulatory approval, the merger is expected to be completed in the fourth quarter of 1995, making it Boston Scientific's fifth acquisition this year. The Natick, Massachusetts-based company will offer up to 10.5 million common shares for Meadox Medicals, a privately-held company estimated to hold some 80% of the US market for vascular replacement or repair devices.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.